Table 1.
Novel direct acting antivirals in clinical trials in chronic HBV infection.
| Drug Family | Drug Name | Trial N | Phase | Status | Sponsor |
|---|---|---|---|---|---|
| Entry inhibitor | Bulevirtide (Myrcludex B) | NCT02881008 | 2 | Completed | Hepatera Ltd. |
| NCT02637999 | 2 | Completed | Hepatera Ltd. | ||
| NCT04166266 | 2 | Not yet recruiting | Inserm-ANRS | ||
| NCT03546621 | 2 | Completed | Hepatera Ltd. | ||
| NCT02888106 | 2 | Recruiting | Hepatera Ltd. | ||
| NCT03852719 | 3 | Recruiting | MYR GmbH | ||
| NCT03852433 | 2 | Recruiting | MYR GmbH | ||
| Small interfering RNA molecules (siRNAs) | VIR-2218 | NCT03672188 | 2 | Recruiting | Vir Biotechnology, Inc. |
| DCR-HBVS | NCT03772249 | 1 | Recruiting | Dicerna Pharmaceuticals | |
| JNJ-3989 (formely ARO-HBV) | NCT03365947 | 1 | Recruiting | Arrowhead Pharmaceuticals | |
| NCT04208386 | 1 | Recruiting | Janssen Sciences | ||
| ARB-1467 | NCT02631096 | 2 | Completed | Arbutus Biopharma Co | |
| Antisense oligonucleotides | GSK3389404 | NCT03020745 | 2 | Completed | GlaxoSmithKline |
| RO7062931 (also known as RG6004) | NCT03038113 | 2 | Completed | Hoffmann-La Roche | |
| GSK 3,228,836 (IONIS-HBVRx) | NCT02981602 | 2 | Completed | GlaxoSmithKline | |
| Capsid inhibitors | GLS4 (Morphothiadin mesilate/ritonavir) | NCT03638076 | 2 | Recruiting | Sunshine Lake Pharma |
| JNJ 56136379 | NCT03361956 | 2 | Active, not recruiting | Janssen Sciences | |
| JNJ 56,136,379 + JNJ 73763989 | NCT04129554 | 2 | Recruiting | Janssen Sciences | |
| JNJ 56,136,379 + JNJ 73763989 | NCT03982186 | 2 | Recruiting | Janssen Sciences | |
| ABI-H0731 | NCT03577171 | 2 | Completed | Assembly Biosciences | |
| NCT03576066 | 2 | Completed | Assembly Biosciences | ||
| NCT03780543 | 2 | Active, not recruiting | Assembly Biosciences | ||
| ABI-H2158 | NCT03714152 | 1 | Recruiting | Assembly Biosciences | |
| NCT04083716 | 1 | Completed | Assembly Biosciences | ||
| QL-007 | NCT04157699 | 2 | Recruiting | Qilu Pharmaceutical | |
| NCT04157257 | 2 | Recruiting | Qilu Pharmaceutical | ||
| RO7049389 (also known as RG7907) | NCT02952924 | 1 | Recruiting | Hoffmann-La Roche | |
| EDP-514 | NCT04008004 | 1 | Recruiting | Enanta Pharmaceuticals | |
| Capsid inhibitor + TLR7 | RO7049389 + RO7020531 (also known as RG7854) | NCT04225715 | 2 | Not yet recruiting | Hoffmann-La Roche |
| HBsAg release inhibitors | REP 2139 | NCT02876419 | 2 | Active, not recruiting | Replicor Inc. |
| REP 2139-Mg + REP 2165-Mg | NCT02565719 | 2 | Completed | Replicor Inc. | |
| REP 2139-Ca | NCT02726789 | 2 | Completed | Replicor Inc. | |
| REP 2139-Ca | NCT02233075 | 2 | Completed | Replicor Inc. |
Note: No preclinical data are included. Only clinical trials completed within the last 2 years are included. Data are drawn from ClinicalTrials.gov.